EbsArgent
EbsArgent is a first-in-class bactericidal antibiotic for urinary tract infections (UTIs) caused by antibiotic-resistant bacteria. It uses a novel mechanism of action, combining silver ions and ebselen to disable the bacterial thioredoxin enzyme system. This approach aims to combat the growing global health threat of multidrug-resistant UTIs.
Buy Funded Startups lists
Funding Round: Series A
Funding Amount: $2.4M
Date: 30-Oct-2024
Investors: Mikael Lönn, MD, Jens Mogensen, GU Ventures, Vasa Angels, Annexstruktur, Gobia Enterprises
Markets: Pharmaceuticals, Antibiotic, Healthtech
HQ: Solna, Stockholm, Sweden
Founded:
Website: http://www.thioredoxinsystems.com/
Leave a Comment
Comments
No comments yet.